Direct answer
Flow cytometry is a laboratory test that passes cells one by one through a laser to measure their size, internal granularity and the proteins (markers) on or inside them. Flow cytometry is used mainly to characterise blood, bone marrow and fluid samples in suspected leukaemia, lymphoma and immune disorders, and to monitor treatment response.
Key takeaways
- Flow cytometry identifies and counts cell populations by their marker pattern (immunophenotype), cell by cell.
- Flow cytometry is a characterisation test, not a screening test for cancer in general, it does not detect most solid tumours.
- Flow cytometry usually needs a fresh blood, bone marrow, body-fluid or fresh tissue sample; delays and clotted or fixed samples degrade results.
- A flow cytometry report describes what was seen in the sample submitted; a negative report does not exclude disease elsewhere in the body.
- Flow cytometry results are interpreted together with the blood counts, smear, bone marrow morphology, biopsy histopathology and genetic tests.
At a glance
| Item | Detail |
|---|---|
| What it measures | Cell size (forward scatter), granularity (side scatter) and fluorescent antibody-tagged surface or intracellular markers; DNA content in some assays |
| Common samples | Peripheral blood (EDTA or heparin as the lab specifies), bone marrow aspirate, lymph node or tissue in special medium, CSF, pleural or ascitic fluid |
| Preparation | Usually no fasting; sample timing and transport matter more than patient preparation |
| Discomfort | Related to the sample collection (venepuncture, bone marrow aspiration, biopsy), not to the analysis itself |
| Typical uses | Leukaemia and lymphoma diagnosis and subtyping, minimal/measurable residual disease, CD4 counts in HIV, PNH testing, CD34 stem cell enumeration, immunodeficiency work-up |
| Who interprets | A haematopathologist or laboratory physician, alongside your treating haematologist or oncologist |
Also known as
- Immunophenotyping (the commonest clinical use of flow cytometry)
- FCM / flow test
- "CD marker test" or "marker panel", the term most Indian patients see on a prescription
- Peripheral blood immunophenotyping (PBIP), bone marrow immunophenotyping
- MRD testing / "flow MRD" in leukaemia follow-up
- CD4 count (a flow cytometry test) in HIV care
- PNH clone testing / FLAER assay
What flow cytometry is
Flow cytometry is an automated cell-analysis method. The laboratory suspends cells in fluid, tags them with antibodies carrying fluorescent dyes, and streams them single-file past one or more lasers. Detectors record how each cell scatters light and which dyes it carries. Software then plots thousands to millions of cells, and the pathologist "gates" on populations of interest.
The clinical value of flow cytometry lies in pattern recognition. Normal lymphocytes, plasma cells, granulocytes and blasts each carry a predictable combination of CD markers. An abnormal population shows an unusual combination, unusually bright or dim expression, or loss of a marker that should be present. That pattern, not any single marker, is what allows a haematopathologist to suggest a diagnosis.
Flow cytometry is distinct from flow sorting (FACS), where selected cells are physically collected; sorting is largely a research and cell-therapy technique rather than a routine diagnostic service.
Why flow cytometry is done
- Suspected acute leukaemia: to confirm blasts and classify them as myeloid, B-lymphoid or T-lymphoid, which directly changes treatment.
- Chronic lymphoproliferative disorders: to detect a clonal B-cell population (for example kappa/lambda light-chain restriction) in suspected CLL or lymphoma involving blood or marrow.
- Lymphoma staging: to check marrow, CSF or effusion fluid for involvement.
- Measurable residual disease (MRD): to detect small numbers of surviving leukaemic cells after treatment, at a sensitivity that a microscope cannot reach.
- Plasma cell disorders: to identify aberrant plasma cells in myeloma work-up.
- HIV care: CD4/CD8 counting for immune status and treatment monitoring.
- Paroxysmal nocturnal haemoglobinuria (PNH): detection of GPI-anchor-deficient clones in unexplained haemolysis, cytopenias or unusual-site thrombosis.
- Primary immunodeficiency: lymphocyte subset analysis in children with recurrent severe infections.
- Stem cell transplant: CD34+ cell enumeration in the graft.
- Unexplained persistent cytopenias or lymphocytosis: to look for a clonal population.
Who should get this test
Flow cytometry is not a general health check-up test and is not ordered on its own. It is appropriate when a doctor already suspects a specific cell-based problem. Typical candidates include people with:
- Blasts or abnormal cells reported on a peripheral blood smear
- Persistent unexplained lymphocytosis, or lymphocytopenia
- Unexplained cytopenias (low haemoglobin, white cells or platelets) needing marrow evaluation
- Lymph node or spleen enlargement under evaluation for lymphoma
- Known leukaemia or lymphoma needing response or MRD assessment
- HIV infection needing CD4 monitoring
- Unexplained haemolysis, dark morning urine, or thrombosis at unusual sites where PNH is considered
- Children with recurrent, severe or unusual infections suggesting immunodeficiency
- A body-fluid or CSF sample where malignant cells are suspected
Flow cytometry is not indicated for routine anaemia, routine fever, ordinary infections or general cancer screening.
What flow cytometry cannot detect or exclude
- It does not screen for cancer generally. Flow cytometry has little role in detecting most solid tumours such as breast, lung, colon or prostate cancer.
- It analyses only the sample submitted. A normal blood immunophenotype does not exclude lymphoma in a lymph node, and a normal marrow result does not exclude disease at other sites.
- It cannot show tissue architecture. Distinguishing follicular lymphoma from reactive follicular hyperplasia, or grading a lymphoma, needs histopathology with immunohistochemistry.
- It can miss fragile or sparse cells. Hodgkin lymphoma cells, some large-cell lymphomas and fibrotic ("dry tap") marrows are poorly represented in flow cytometry samples; a negative result in these settings is unreliable.
- It does not identify genetic abnormalities. Translocations, fusion genes and mutations require karyotyping, FISH, PCR or next-generation sequencing. Flow cytometry may suggest, but cannot confirm, these.
- A negative MRD result is not proof of cure. MRD below the assay's limit of detection means disease was not identified at that sensitivity, not that no leukaemic cell remains.
- It cannot diagnose infection type. Flow cytometry shows the immune response pattern, not the organism; cultures and molecular tests are needed for that.
If symptoms persist despite a normal or unremarkable flow cytometry report, return to the doctor who requested the test. "Not identified" is not the same as "excluded".
Related but different examinations
| Test | Question it answers | Key difference from flow cytometry |
|---|---|---|
| Complete blood count (CBC) with peripheral smear | Are the counts and cell shapes abnormal? | First-line and inexpensive; flags the problem but cannot define cell lineage or clonality |
| Bone marrow aspiration and biopsy (morphology) | What do the marrow cells look like, and how is the marrow structured? | Shows architecture, fibrosis and cellularity; flow cytometry is usually run on the same aspirate as a complement |
| Immunohistochemistry (IHC) on tissue | Which markers do cells express within intact tissue? | Preserves architecture and detects fragile cells flow cytometry may lose; slower and less quantitative |
| Cytogenetics / FISH / molecular testing | Which chromosomal or gene abnormality is present? | Defines genetic risk group and targeted therapy eligibility; flow cytometry cannot do this |
| Molecular MRD (PCR / NGS) | Is residual disease present at a genetic level? | Often more sensitive for specific markers; flow MRD is faster and applicable when no molecular marker exists |
| Serum protein electrophoresis and free light chains | Is there a monoclonal protein? | Blood protein test; flow cytometry looks at the plasma cells themselves |
| Flow sorting (FACS) | Can specific cells be physically collected? | Mainly research and cell-therapy use, not routine diagnostics |
These tests answer different questions. None is universally superior; which comes first depends on the clinical presentation. A swollen lymph node usually leads to biopsy with histopathology first, while abnormal circulating cells usually lead to blood flow cytometry first.
How to prepare
Preparation, tube type, transport time and panel composition are decided by the performing laboratory. Protocols vary between facilities, and the written instructions given by your own collection centre take precedence over anything here.
- Fasting: generally not required for flow cytometry itself. If other tests are being drawn at the same time, follow the fasting instruction for those.
- Timing: flow cytometry needs living, intact cells. Laboratories set strict limits on how long a sample may be held before processing, which is why appointments are often scheduled early in the day.
- Medicines: tell the requesting doctor about steroids, chemotherapy, immunosuppressants, growth factors (such as G-CSF), recent blood transfusions and monoclonal antibody therapy such as rituximab, all can alter cell populations. Do not start, stop or adjust any prescribed medicine yourself; speak to the prescriber.
- Recent treatment: mention any treatment received in the preceding days, including AYUSH or over-the-counter preparations.
- Procedure-based samples: for bone marrow aspiration or biopsy, the unit will give separate instructions on bleeding risk, blood thinners, sedation and an escort.
Pregnancy
Flow cytometry involves no radiation and no contrast. Blood-based flow cytometry is straightforward in pregnancy. If a bone marrow procedure or biopsy is required, positioning, sedation and analgesia are adjusted by the treating team.
Children
Paediatric sample volumes are limited, so panels may be prioritised. Marrow sampling in children is often done under sedation or general anaesthesia, and fasting instructions then apply.
People with bleeding tendency or on blood thinners
Venepuncture is usually manageable with prolonged pressure. Bone marrow aspiration and biopsy need review of anticoagulant and antiplatelet therapy by the treating doctor beforehand.
People with low immunity
Standard aseptic technique applies. If you are neutropenic, tell the collection staff so that the sampling site can be handled with extra care.
What happens during flow cytometry
- Sample collection: blood is drawn from an arm vein into a specified tube; marrow is aspirated from the posterior iliac crest or sternum under local anaesthetic; fluids and tissue are collected by the relevant procedure.
- Transport: the sample travels to the laboratory at a controlled temperature, unfixed.
- Staining: the laboratory splits the sample into tubes, adds antibody cocktails, lyses red cells and washes the preparation. Intracellular markers require permeabilisation.
- Acquisition: cells run through the cytometer; scatter and fluorescence signals are recorded.
- Analysis: a haematopathologist gates populations, compares them with normal patterns and writes an interpretive report.
How long the process takes
- Blood draw: a few minutes.
- Bone marrow aspiration and biopsy: commonly around 15-30 minutes including positioning and local anaesthetic, with a short observation period afterwards.
- Laboratory staining and acquisition: usually a few hours of hands-on work once the sample reaches the laboratory.
- Interpretation and reporting: depends on panel complexity, whether additional tubes are needed after the first look, and whether the case is discussed with the treating team. Extended panels such as MRD or PNH generally take longer than a basic lymphocyte subset panel.
Your laboratory will tell you the expected reporting time for your specific panel.
Understanding your flow cytometry report
A flow cytometry report is descriptive, not a simple number. Typical elements include:
- Sample and adequacy: the specimen type, viability and whether enough cells were available.
- Panel used: the list of CD markers tested (for example CD45, CD34, CD19, CD20, CD3, CD5, CD10, CD13, CD33, kappa and lambda).
- Populations identified: percentages of blasts, lymphocytes, monocytes, granulocytes or plasma cells, and where they sit on CD45 versus side scatter.
- Abnormal population description: its size as a percentage of events, and the markers it expresses or has lost.
- Interpretation: a statement such as "findings are consistent with B-lymphoblastic leukaemia" or "no abnormal population identified", often with a recommendation for correlation with morphology and genetics.
Percentages in a flow cytometry report refer to the cells that were analysed in that tube, which is why the same patient can have different percentages in blood and in marrow. Reference values for subsets such as CD4 counts vary with age, laboratory method and instrument, so interpret only against the range printed on your own report. Flow cytometry never diagnoses on its own, the report must be read with the clinical picture, the counts, the biopsy and the genetic results by the doctor who ordered it.
When flow cytometry results can be misleading
Results that can appear falsely abnormal or falsely raised
- Reactive lymphocytosis after viral infection can mimic a lymphoproliferative disorder on scatter plots.
- G-CSF or growth factor therapy can increase immature myeloid cells and CD34 expression, imitating blasts.
- Regenerating marrow after chemotherapy contains hematogones, normal B-cell precursors that can be mistaken for residual leukaemia if not carefully distinguished.
- Dead cells and debris bind antibodies non-specifically and can create spurious populations.
- Spectral overlap or poor compensation between fluorescent dyes can exaggerate apparent marker expression.
Results that can appear falsely normal or falsely lowered
- Haemodilution of a marrow aspirate dilutes the abnormal population and can under-report disease burden, a well-recognised limitation in MRD testing.
- Delayed or poorly transported samples lose cell viability, dropping abnormal populations out of the analysis.
- A dry tap or fibrotic marrow may yield too few cells for a reliable answer.
- Recent steroid therapy can rapidly reduce lymphoid and blast populations, masking disease.
- Anti-CD20 therapy such as rituximab can block or remove the CD20 target, making B cells appear absent or marker-negative.
- Recent blood transfusion can confound PNH clone assessment in red cells.
- Fragile large cells and Hodgkin lymphoma cells are often lost during processing.
- A panel that does not include the relevant marker cannot find the abnormality; some diagnoses need a second, extended panel.
Risks and safety
The analysis itself is performed on a sample and carries no risk to the patient. Risk depends on how the sample is obtained, and differs by method. Results vary depending on individual clinical circumstances.
Blood sample
Minor pain, bruising, and less often a small haematoma or brief light-headedness. Infection at the puncture site is uncommon.
Bone marrow aspiration and biopsy
Pain during aspiration is common and usually brief. Bruising, bleeding and local infection can occur; significant bleeding is uncommon but more likely with low platelets or anticoagulation. Rarely, prolonged site pain occurs.
Tissue biopsy or fluid aspiration
Risks relate to the specific procedure and site, bleeding, infection, pain and, for chest procedures, pneumothorax. The proceduralist will explain the risks relevant to your case and take consent.
Interpretive risk
Complex flow cytometry data can be misread if clinical details and prior treatment are not supplied. Always tell the laboratory and the requesting doctor about recent therapy.
Red flags
Emergency now
- Bleeding from a marrow or biopsy site that soaks through dressings and does not stop with 10-15 minutes of firm pressure
- Breathlessness, chest pain, confusion or collapse after a sampling procedure
- Fever with shaking chills in someone with very low white cell counts
- Rapidly spreading redness, swelling and severe pain at the procedure site
Same day
- Fever above 38癈, or increasing pain, discharge or swelling at the sampling site
- New widespread bruising, petechiae, bleeding gums or nosebleeds
- Rapidly enlarging lymph nodes, drenching night sweats or new severe weakness while awaiting results
- A report labelled critical or urgent by the laboratory
Routine appointment
- Mild soreness or a small bruise at the sampling site settling over a few days
- Questions about an abnormal but non-urgent finding in the report
- Persistent symptoms despite a normal flow cytometry report, this needs re-evaluation, not reassurance
Special situations
Pregnancy
Blood-based flow cytometry is safe to perform during pregnancy. Normal pregnancy alters white cell counts and some lymphocyte subsets, so results should be interpreted with that in mind. Any ultrasound performed alongside must follow the PC-PNDT Act 1994, which prohibits disclosure of foetal sex.
Children
Lymphocyte subset reference values in children differ substantially from adults and change with age; adult ranges must not be applied. Hematogones are abundant in paediatric marrow and require experienced interpretation to avoid confusion with residual leukaemia.
Older adults
Small clonal B-cell populations (monoclonal B-cell lymphocytosis) are detected more often with age and frequently do not require treatment. Interpretation must be conservative and clinically anchored.
People on chemotherapy or immunosuppressants
Counts and marker expression shift with therapy. Timing relative to a treatment cycle changes results, so the laboratory needs the treatment date and drug names.
People living with HIV
CD4 counts are a flow cytometry measurement and fluctuate with intercurrent infection, diurnal variation and steroid use. Trends over time are more informative than a single value.
People with anaemia or thalassaemia trait
Iron-deficiency anaemia and haemoglobinopathies are common in India and can alter blood counts, but they do not invalidate immunophenotyping. They do, however, influence how a cytopenia is worked up and which tests come first.
Flow cytometry in the Indian context
- Availability: diagnostic flow cytometry is concentrated in tertiary hospitals, cancer centres and large reference laboratories. Samples from smaller towns are often couriered, which makes transport time and temperature control the main determinants of sample quality.
- Language on prescriptions: patients commonly encounter the terms "CD marker test", "marker panel", "flow test" or "immunophenotyping" rather than "flow cytometry".
- Infection overlap: tuberculosis, dengue, enteric fever, malaria and HIV are frequent causes of cytopenias, lymphadenopathy and hepatosplenomegaly in India. These can mimic haematological malignancy clinically, and flow cytometry is often used to help distinguish a reactive from a clonal process.
- HIV programmes: CD4 enumeration by flow cytometry is a routine part of HIV care across public and private services.
- Anaemia background: the very high prevalence of iron-deficiency anaemia and of thalassaemia trait in parts of India means abnormal counts are common and must be interpreted carefully before escalating to specialist testing.
- Data protection: laboratory reports and any online booking or report-access tool handle sensitive personal health data governed by the Digital Personal Data Protection Act, 2023.
Cost and insurance in India
There is no single national price for flow cytometry. Cost depends on the panel, not on the machine. The main factors that influence what you pay:
- Number of markers: a limited lymphocyte subset or CD4 panel costs far less than a comprehensive acute leukaemia panel.
- Panel type: MRD, PNH and stem cell enumeration assays use specialised reagents and more analysis time.
- Sample type: bone marrow or tissue sampling adds the cost of the procedure, consumables, day-care use and sometimes sedation.
- Add-on testing: cytogenetics, FISH and molecular studies are billed separately and are often needed alongside.
- Repeat panels: a second-line panel may be required after the first result and is charged additionally.
- Logistics: outstation sample transport and urgent processing can add charges.
- City and sector: metro private laboratories generally price differently from smaller centres and government facilities.
Insurance: flow cytometry performed during an admission or day-care procedure is usually processed under the hospitalisation claim, while purely outpatient diagnostics may fall under OPD benefits only if your policy includes them. Government schemes such as Ayushman Bharat PM-JAY cover defined packages at empanelled hospitals. Confirm coverage and pre-authorisation with your insurer or the hospital TPA desk before testing.
Myths and facts
| Myth | Fact |
|---|---|
| Flow cytometry is a blood test that screens for all cancers | Flow cytometry mainly characterises blood, marrow and lymphoid cells. It has little role in detecting most solid tumours. |
| A normal flow cytometry report means you do not have cancer | The report reflects only the sample analysed. Lymphoma confined to a node or organ can be missed on a blood or marrow sample. |
| Flow cytometry alone confirms the leukaemia diagnosis and treatment | Modern classification and treatment selection also need morphology, cytogenetics and molecular testing. |
| MRD-negative means cured | MRD-negative means no disease was detected at the assay's sensitivity limit. Follow-up continues. |
| Higher percentages in a report always mean worse disease | Percentages depend on the sample, the gate and dilution. They are interpreted alongside absolute counts and the clinical picture. |
| Any laboratory can run the test equally well | Flow cytometry quality depends on panel design, instrument calibration, sample freshness and the experience of the interpreting pathologist. |
Frequently asked questions
What is flow cytometry used for in hospital practice?
Flow cytometry is used to identify and count cell populations by their surface and internal markers. Its commonest clinical uses are diagnosing and subtyping leukaemia and lymphoma, measuring residual disease after treatment, counting CD4 cells in HIV, detecting PNH clones and assessing immune deficiencies in children.
Does flow cytometry hurt?
The analysis itself is done on a sample, so it causes no sensation. Any discomfort comes from collection. A blood draw feels like a routine needle prick. Bone marrow aspiration is done under local anaesthetic and usually causes a brief, sharp pulling pain during the aspiration itself.
Do I need to fast before flow cytometry?
Fasting is generally not required for flow cytometry. However, sample timing matters because the laboratory needs living cells within a defined window. If other tests are drawn at the same sitting, follow the fasting instruction given for those, and follow your own collection centre's written advice.
Can flow cytometry replace a bone marrow biopsy?
No. Flow cytometry is usually run on marrow aspirate fluid and cannot show marrow architecture, fibrosis or overall cellularity. The trephine biopsy provides that structural information. The two tests are complementary and are normally reported together by the haematopathologist.
How is flow cytometry different from immunohistochemistry?
Both detect cell markers. Flow cytometry analyses suspended single cells quickly and quantitatively but loses tissue structure and fragile cells. Immunohistochemistry stains markers within intact tissue sections, preserving architecture. Lymph node diagnoses usually need immunohistochemistry; blood and marrow work often starts with flow cytometry.
Can medicines affect my flow cytometry result?
Yes. Steroids, chemotherapy, growth factors such as G-CSF, monoclonal antibodies such as rituximab and recent transfusions can all change which cells are present and which markers are visible. Tell the requesting doctor and laboratory what you have received and when. Do not change any prescribed medicine yourself.
What does "no abnormal population identified" mean on my report?
It means the laboratory did not find an abnormal cell population in that particular sample using that particular panel. It does not exclude disease elsewhere or below the panel's detection limit. If symptoms persist, return to the doctor who ordered the test for further evaluation.
Is flow cytometry useful in infections?
Indirectly. Flow cytometry can show the immune response pattern, for example a fall in CD4 cells in HIV, or a reactive lymphocyte pattern after a viral illness. Flow cytometry does not identify the organism; cultures, serology and molecular tests are required for that.
Who interprets the flow cytometry report?
A haematopathologist or laboratory physician analyses the data and writes the interpretation, often in discussion with your haematologist or oncologist. The final clinical meaning is decided by the doctor who requested the test, in the context of your symptoms, counts, imaging and other laboratory results.
Sources
- World Health Organization Classification of Haematolymphoid Tumours, 5th edition (2022)
- International Consensus Classification of Myeloid and Lymphoid Neoplasms (Blood, 2022)
- EuroFlow Consortium consensus protocols for immunophenotyping of haematological malignancies
- International Clinical Cytometry Society / ICSH-ICCS practice guidelines on flow cytometric analysis and validation
- National AIDS Control Organisation (NACO), Ministry of Health and Family Welfare, guidelines on HIV care and CD4 monitoring
- Digital Personal Data Protection Act, 2023, Government of India
- Pre-conception and Pre-natal Diagnostic Techniques (Prohibition of Sex Selection) Act, 1994